The US Food and Drug Administration (FDA) has approved Skinvive by Juvéderm to reduce neck lines in adults older than 21.
Skinvive by Juvéderm is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture for an improved neck appearance.
The HA microdroplet injections are placed just under the skin to improve smoothness and increase hydration.
The new regulatory clearance expands the treatment line beyond its initial approval for cheek skin smoothness.
As with some novel products, the FDA has required that Allergan Aesthetics provide a training program for all interested providers. Successful completion of this training is necessary prior to purchase of and administration of Skinvive by Juvéderm.
Allergan Aesthetics anticipates that Skinvive by Juvéderm for the improvement of neck appearance will be broadly commercially available later this year.
In the randomized, multicenter, evaluator-blinded, controlled pivotal clinical study, 74.8% of participants treated in the neck with Skinvive by Juvéderm saw clinically significant (≥ one point) improvement on the validated five-grade photonumeric Allergan Transverse Neck Lines Scale (ATNLS) at one month. Most participants maintained ≥ one point improvement in horizontal neck lines at six months. Participants who demonstrated improvement from baseline in overall score stayed high (≥78%) at all time points during the study.
Participants in the clinical study reported experiencing adverse events (AEs) such as redness, bruising, tenderness, lumps/bumps, swelling, firmness, pain, discoloration, and itching at the injection sites, as reported in their electronic diaries. These AEs were usually mild, did not require treatment, and resolved within two weeks. Severe AEs were experienced by less than 5% of participants. These AEs were reported similarly or less frequently after touch-ups and repeat treatments.
